GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Protein-calorie malnutrition in patients with COPD exacerbation is linked to higher risk for mortality, AKI, respiratory ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit ...

GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...

UK pharma major GSK and US clinical-stage biotech Empirico, with leading capabilities in human genetics-driven target ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...

Regeneron Pharmaceuticals and Sanofi have completed a Phase 3 clinical study titled Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to E ...

A significant link was found between active cigarette smoking and an elevated rate of pneumonia in COPD, whereas this was not ...

Respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) are on the rise partly because of ...

Anti-IL5 therapy significantly reduces moderate and severe exacerbations in asthma and COPD, preventing major ...